hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
== Structure == The structure of a polymeric material can be described at different length scales, from the sub-nm length scale up to the macroscopic one. There is in fact a hierarchy of structures, in which each stage provides the foundations for the next one. The starting point for the description of the structure of a polymer is the identity of its constituent monomers. Next, the microstructure essentially describes the arrangement of these monomers within the polymer at the scale of a single chain. The microstructure determines the possibility for the polymer to form phases with different arrangements, for example through crystallization, the glass transition or microphase separation. These features play a major role in determining the physical and chemical properties of a polymer.
=== Political culture === In 1935, elections were reinstated, but only 1.8 per cent of the population was eligible to vote. In 1954, women won the right to vote. Since 1974, the party system in Belize has been dominated by the centre-left People's United Party and the centre-right United Democratic Party, although other small parties took part in all levels of elections in the past. Though none of these small political parties has ever won any significant number of seats or offices, their challenge has been growing over the years.
=== Anaesthesia === Labial reduction can be performed under local anaesthesia, conscious sedation, or general anaesthesia, either as a discrete, single surgery, or in conjunction with another, gynecologic or cosmetic, surgery procedure. The resection proper is facilitated with the administration of an anaesthetic solution (lidocaine + epinephrine in saline solution) that is infiltrated to the labia minora to achieve the tumescence (swelling) of the tissues and the constriction of the pertinent labial circulatory system, the hemostasis that limits bleeding.
As flour fortification started adding niacin in the US, the United States Government adopted the terms niacin (a shortened form of "nicotinic acid vitamin") and niacinamide in 1942 as alternate names for nicotinic acid and nicotinamide, respectively, and encouraged their use in nontechnical contexts to avoid the public confusing them with the nearly unrelated (and toxic) nicotine. The terms were incorporated into the United States Adopted Name dictionary that was created in 1961. The term niacin was then adopted internationally by multiple institutions (WHO/FAO, EFSA, FDA, Anvisa) using a broader meaning including all dietary NAD precursors that can prevent signs of deficiency. In other words, the term is used with the same meaning as vitamin B3, including not just nicotinic acid, but also nicotinamide, and nicotinamide riboside. The term niacinamide failed to replace nicotinamide. Between 1942 and 2022, it has never surpassed nicotinamide in terms of occurrence in published books, according to Google Ngram Viewer.
"Impact of elevated CO2 on shellfish calcification". Geophysical Research Letters. 34 (7): L07603. Bibcode:2007GeoRL..34.7603G. doi:10.1029/2006GL028554. hdl:20.500.11755/a8941c6a-6d0b-43d5-ba0d-157a7aa05668. Gattuso, J.-P.; Hansson, L.; "Ocean acidification" (Oxford University Press) Kroeker, K.; Kordas, R.; Crim, R.; Hendriks, I.; Ramajo, L.; Singh, G.; Duarte, C.; Gattuso, J.-P. (2013). "Impacts of ocean acidification on marine organisms: quantifying sensitivities and interaction with warming". Global Change Biology. 19 (6): 1884–1896. Bibcode:2013GCBio..19.1884K. doi:10.1111/gcb.12179. PMC 3664023. PMID 23505245. Gattuso, J.-P.; Magnan, A.; Billé, R.; Cheung, W.W.L.; Howes, E.L.; Joos, F.; Allemand, D.; Bopp, L.; Cooley, S.; Eakin, C.M.; Hoegh-Guldberg, O.; Kelly, R.P.; Pörtner, H.; Rogers, A.D.; Baxte, J.M.; Laffoley, D.; Osborn, D.; Rankovic, A.; Rochette, J.; Sumaila, U. R.; Treyer, S.; Turley, C. (2015). "Contrasting futures for ocean and society from different anthropogenic CO2 emissions scenarios" (PDF). Science. 349 (6243) aac4722. doi:10.1126/science.aac4722. PMID 26138982. S2CID 206639157. Magnan, A.K.; Colombier, M.; Billé, R.; Hoegh-Guldberg, O.; Joos, F.; Pörtner, H.-O; Waisman, H.; Spencer, T.; Gattuso, J.-P. (2016). "Implications of the Paris Agreement for the ocean". Nature Climate Change. 6 (8): 732–735. Bibcode:2016NatCC...6..732M. doi:10.1038/nclimate3038. Gattuso, J.-P.; Williamson, P.; Duarte, C.; Magnan, A.K. (2021). "The potential for ocean-based climate action: negative emissions technologies and beyond". Frontiers in Climate. 2 575716.
Sources: en.wikipedia.org
== Behavior == Not much is known about N. christyi. However, it is believed to be active by day and night. It is a semi-aquatic snake which spends much of its time in the water. An excellent swimmer. It tends to hide amongst rocks, in holes or overhanging tree roots at the shore line. It also makes use of any man-made structures such as bridges and jetties to hide. Generally this is not an aggressive snake, so bites are rare. If approached in water it will swim away swiftly. If threatened on land it will rear up, spread its narrow hood and hiss. It may strike if it's provoked extensively.
=== EURATOM === The European Atomic Energy Community (EURATOM) was founded on March 25, 1957, by the Treaty of Rome between France, Italy, the Benelux countries and the Federal Republic of Germany, and remains almost unchanged to this day. Chapter 3 of the Euratom Treaty regulates measures to protect the health of the population. Article 35 requires facilities for the continuous monitoring of soil, air and water for radioactivity. As a result, monitoring networks have been set up in all Member States and the data collected is sent to the EU's central database (EURDEP, European Radiological Data Exchange Platform). The platform is part of the EU's ECURIE system for the exchange of information in the event of radiological emergencies and became operational in 1995. Switzerland also participates in this information system.
=== Genetic heterogeneity === Historically, "Ca. M. multicellularis" was thought to be entirely clonal due to its synchronous cell division. However, single-consortium metagenome (SCM) sequencing has revealed that the individual cells within each organism are genetically heterogeneous. The constituent cells feature distinct single-nucleotide polymorphisms (SNPs) situated randomly across their genomes.
=== Road freight === Transport by road is by far the most popular means of moving freight around South Africa. As of October 2025, over 85% of land freight in SA travels by road. For every ton of freight moved by rail, more than six tons is moved by road. Each year, almost 1 billion tons (984 million) of freight is transported along South Africa's road networks. This is an increase of over 50% over the period between 2010 and 2025. National roads in South Africa are administered by SANRAL, a state-owned company that reports to the Department of Transport. SANRAL is responsible for financing, managing, planning, developing, and maintaining the national road network. Municipalities also have control over and put funding into certain roadways. Certain avenues of private funding for roadways in South Africa also exist.
In the last episode of season three, Mark proposes to Sarah and it is revealed in the first episode of the fourth season that she accepted. Sarah goes to work for photographer Hank Rizzoli. In season 4, episode 10, "Trouble in Candyland", Mark breaks up with Sarah because of her habit of running away from things that make her feel good about herself. This happens after Sarah puts her job before Mark when she turned down going to a wedding with him so she could accompany her boss to a photography job in Los Angeles. In season five she becomes the superintendent of an apartment building before becoming Hank's photography partner full-time. Hank and Sarah marry in the series finale.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.